In Kerala's tropical, humid climate with high UV exposure, concurrent use of broad-spectrum SPF 50+ UVA/UVB sunscreen is mandatory to prevent photodamage and mitigate PIH risk
Adverse events in relation to GLP-1R agonists for the treatment of obesity are mainly gastrointestinal side effects, including nausea, diarrhoea, vomiting and constipation, which is consistent with observations in type 2 diabetes, and rates of discontinuation due to adverse events are generally higher with GLP-1R agonists treatment compared with placebo [26, 30,31,32,33,34,35,36,37,38,39]
Precise incidence rates for bloating specifically are not comprehensively reported in tirzepatide clinical trials, as these symptoms may be captured under broader categories such as "abdominal distension," "dyspepsia," or "abdominal discomfort." However, gastrointestinal adverse events collectively affect a substantial proportion of patients receiving tirzepatide therapy
Marketing of compounded GLP-1s often lacks safety information
Doctors monitor patients for side effects and adjust the dose as needed
Chidester has set out to make these issues a thing of the past by asking patients to pause GLP-1s for six weeks before and six weeks after surgery to bolster nutrition